Spacer
Spacer Home  |  Contact Us Spacer
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.
spacer
Banner for News pages
spacer
spacer

Alvine Pharmaceuticals to Present at the J.P. MORGAN 27th Annual Healthcare Conference

SAN CARLOS, Calif., January 7, 2009 - Alvine Pharmaceuticals, Inc. today announced that its President and Chief Executive Officer, Abhay Joshi, Ph.D., will present at the J.P. Morgan 27th Annual Healthcare Conference in San Francisco, California on January 12, 2009 at 11:30 a.m. PST.

In October 2008, Alvine announced positive proof of concept in a Phase I Trial of ALV003, an oral protease therapy in development to detoxify gluten, intended for use by patients with celiac disease.  The trial results confirmed that single doses of up to 1,800 mg of ALV003 were safe and tolerable in healthy volunteers.  Doses at the 300 mg level achieved up to a 96% reduction of gluten in a meal in the stomach at 30 minutes, and were well tolerated by patients with celiac disease.  In addition, doses as low as 100 mg were shown to be biologically active in degrading gluten in the stomach.  Based on these results, Alvine plans to initiate Phase I/IIa multidose trials in early 2009.

About Alvine

Alvine Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing therapeutics for autoimmune/gastrointestinal diseases. Alvineā€™s lead product candidate, ALV003, is a combination protease engineered to degrade gluten, and is being developed to treat patients with celiac disease.  For additional information about the company, please visit http://www.alvinepharma.com.

About ALV003

ALV003 is an orally administered combination of two recombinant proteases engineered to degrade gluten into non-immunotoxic fragments, by targeting the glutamine and proline residues that are common in gluten.  ALV003 consists of a glutamine specific cysteine protease (EP-B2) and a proline specific prolyl endopeptidase (PEP).

About Celiac Disease

Celiac disease is the most common hereditary autoimmune disease with prevalence as high as 2% in the U.S. and E.U.  Celiac disease is triggered by the ingestion of gluten in genetically susceptible individuals.  Gluten is a protein found naturally in wheat, rye, and barley, and is one of the most common and nutritionally significant ingredients in the human diet.  Patients with celiac disease mount an immune response to gluten and gluten fragments, resulting in systemic immune mediated damage in the gut and other organs.  Gluten ingestion can be associated with symptoms such as nausea, diarrhea, constipation and rash.  Complications of celiac disease can include osteoporosis, anemia, dermatitis, weight loss, diabetes, central nervous system conditions, other autoimmune diseases and malignancies.  The only available option for individuals diagnosed with celiac disease today is a life-long adherence to a strict gluten-free diet, which is difficult to follow.


Contact:
Kirk Essenmacher M.D., M.B.A.
Phone: (650) 596-2434
Vice President of Marketing, Corporate and Strategic Development


Back To Top
 

www.clinicaltrials.gov >>   

spacer
spacer

Location

Alvine Pharmaceuticals, Inc.
Headquarters
75 Shoreway Rd., Suite B
San Carlos, CA 94070
view all contact info >>

Business Inquiries

Kirk Essenmacher, M.D., M.B.A.
T: (650) 596-2434
E: email BD >>

Clinical Inquiries

E: email info@alvinepharma.com >>

spacer
spacer